India Rejects Patent for Shorter Drug-Resistant TB Treatment
India has turned down a patent application for a shorter treatment for drug-resistant tuberculosis. The decision could allow more generic companies to compete. Its effect on treatment costs will depend on drug availability, pricing and access to care.
Context
Context: A patent gives a company exclusive rights to sell a drug, so rejecting one can let cheaper generic versions enter the market. TB is still a major health burden in India, and drug-resistant strains take longer and cost more to treat.
Burning Potato score: 71%